Evidence map›Paper›PMID 42062487›Full record

ArticleScientific reports2026

Prebiotic intervention changes host and microbe proteomes in plasma extracellular vesicles of Parkinson's disease.

Deepak Sharma, Robin M Voigt, Deborah A Hall, Thaisa M Cantu-Jungles, Maliha Shaikh, Phillip A Engen, Jeff Jones, Shan Li, Bruce R Hamaker, Christopher B Forsyth and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Deepak SharmaBainom Inc., 750 North State Street, Chicago, IL, USA.
Robin M VoigtRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA.
Deborah A HallDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Thaisa M Cantu-JunglesWhistler Cener for Carbohydrate Research, Department of Food Science, Purdue University, West Lafayette, IN, USA.
Maliha ShaikhRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA.
Phillip A EngenRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA.
Jeff JonesDivision of Physics, Mathematics and Astronomy, California Institute of Technology, Pasadena, CA, USA.
Shan LiDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Bruce R HamakerWhistler Cener for Carbohydrate Research, Department of Food Science, Purdue University, West Lafayette, IN, USA.
Christopher B ForsythRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA.
Faraz BishehsariRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA.
Erika G Marques de MenezesVitalant Research Institute, San Francisco, CA, USA.
Philip J NorrisVitalant Research Institute, San Francisco, CA, USA.
Christopher G GoetzDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Ali KeshavarzianRush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, USA. Ali_Keshavarzian@rush.edu.ORCID http://orcid.org/0000-0002-7969-3369

Funding

NIH HHS 1U01DK140923-01
6 · The paper itself

Abstract

We hypothesize that intestinal microbiome dysbiosis may contribute to Parkinson's disease (PD) pathogenesis. Our prior proof-of-concept clinical trial demonstrated that a precision prebiotic intervention improved microbiota dysbiosis and alleviated gastrointestinal and motor symptoms in PD patients. Building on this, we analyzed plasma extracellular vesicles (EVs) from participants to explore EVs as a dynamic PD biomarker and to assess the systemic effects of a microbiota-directed intervention. Using mass spectrometry-based proteomics of EVs from PD and healthy control (HC) participants, we identified distinct human and bacterial proteins in plasma-derived EV. Crucially, this offers a holistic systemic readout of the microbiota-gut-brain axis by quantifying both host and microbial components. We found that EV proteomic profiles differed between PD and HC samples as well as between unmedicated/mild and medicated/moderate PD participants. Furthermore, the microbiota-directed prebiotic intervention induced an acutely modifiable PD signature, shifting host and microbial EV proteomic profiles toward the HC profile. Using a combined 16-feature host-microbe signature, we built a multiple linear regression model that accurately distinguishes PD status from HC (R

Indexed as

Extracellular VesiclesParkinson DiseasePrebioticsProteomeAgedBiomarkersDysbiosisFemaleGastrointestinal MicrobiomeHumansMaleMiddle AgedProteomicsBiomarkersPrebioticsProteome

Identifiers

PMID42062487
PMCPMC13323702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.